| P50 | author | Jun Yong Park | Q58221011 |
| | Sang Hoon Ahn | Q63436666 |
| | Kwang-Hyub Han | Q63436668 |
| P2093 | author name string | Soo-Ok Kim | |
| | Sun Pyo Hong | |
| | Wangdon Yoo | |
| | Soo-Kyung Shin | |
| | Ji-Yong Chun | |
| P2860 | cites work | Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus | Q28379014 |
| | Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments | Q30830513 |
| | Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization | Q30853725 |
| | Population genotyping of hepatitis C virus by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of short DNA fragments. | Q33214991 |
| | Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil | Q33233245 |
| | Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough | Q33240085 |
| | Single-nucleotide polymorphisms: analysis by mass spectrometry | Q33283978 |
| | Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients. | Q33284655 |
| | Selection of precore mutants during lamivudine treatment in patients with chronic hepatitis B. | Q33360359 |
| | Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5' untranslated region using a matrix assisted laser desorption/ionization time of flight-based assay, restriction fragment mass polymorphism | Q33361381 |
| | High-resolution human papillomavirus genotyping by MALDI-TOF mass spectrometry | Q33366978 |
| | Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa | Q33633648 |
| | Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures | Q34302587 |
| | Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 |
| | Hepatitis B and hepatocellular carcinoma | Q34618351 |
| | A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine. | Q53365502 |
| | Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. | Q53406737 |
| | Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. | Q54599747 |
| | Phenotypic Assays and Sequencing Are Less Sensitive Than Point Mutation Assays for Detection of Resistance in Mixed HIV-1 Genotypic Populations | Q56778549 |
| | Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B | Q57487519 |
| | Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B | Q82822290 |
| | Viral hepatitis B. | Q35617319 |
| | Entecavir: a new treatment option for chronic hepatitis B. | Q36413174 |
| | Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. | Q36780274 |
| | Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. | Q36882276 |
| | Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma | Q37214128 |
| | Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China | Q37278075 |
| | Strategies for global prevention of hepatitis B virus infection | Q37703023 |
| | The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B. | Q38509468 |
| | A potent inhibitor of Taq polymerase copurifies with human genomic DNA. | Q40556812 |
| | Genotypic resistance to entecavir in chronic hepatitis B patients | Q42981198 |
| | Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. | Q43202400 |
| | Interference of heparin with the polymerase chain reaction. | Q44530169 |
| | Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. | Q44671796 |
| | Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis | Q46415674 |
| | Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients | Q46540171 |
| | A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients | Q46757241 |
| | Virologic response and resistance to adefovir in patients with chronic hepatitis B. | Q46842950 |
| | A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. | Q46981468 |
| | Predicting cirrhosis risk based on the level of circulating hepatitis B viral load | Q46985831 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | entecavir | Q418586 |
| | chronic hepatitis | Q62019625 |
| P304 | page(s) | 399-408 | |
| P577 | publication date | 2013-12-28 | |
| P1433 | published in | Clinical and molecular hepatology | Q26853927 |
| P1476 | title | Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B | |
| P478 | volume | 19 | |